Last updated: 2026-09-08 11:02:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Monopar Therapeutics Inc. (MNPR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $117.00, with a market capitalization of $789.08M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $41.12 to $124.82. This page covers its latest market performance, valuation, price trends and company information.
$789.08M | |
$117.00 | |
$240.00 | |
$1.37 | |
-- | |
2.86K | |
219.72K | |
-- | |
$124.82 | |
$41.12 | |
-- | |
-- |
Monopar Therapeutics Inc. (MNPR) is trading at $116.51 in pre-market trading as of 2026-09-08 10:49:00, -- from the previous close of $0.00
Pre-market trading shows how investors are pricing MNPR before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, Monopar Therapeutics Inc. (MNPR) moved from $113.94 to $117.00, representing a gain of 2.69% ($3.06).
The stock traded between $106.67 and $121.02 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 156.51 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.7%
MNPR is currently trading at $117.00, placing it 90.7% of the way from its 52-week low of $41.12 to its 52-week high of $124.82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 22 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Monopar Therapeutics Inc. (MNPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.